<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial</h1>

    <table>
      <tr><th>Ticker</th><td>PLYX</td></tr>
      <tr><th>Float</th><td>4.1 M</td></tr>
      <tr><th>IO</th><td>N/A</td></tr>
      <tr><th>MC</th><td>187 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Polaryx Therapeutics (NASDAQ: PLYX) selected a contract research organization (CRO) to run SOTERIA, a Phase 2, open-label, single-arm basket trial of PLX-200 across four lysosomal storage disorders (CLN2, CLN3, Krabbe, Sandhoff). The company received an FDA "safe to proceed" letter in October 2025 and plans to initiate the trial in the first half of 2026 at sites in the U.S., Europe and Asia. PLX-200 is an oral, gemfibrozil-based compound with documented blood-brain barrier penetration and an established safety profile in adults. CLN2 and CLN3 cohorts will incorporate natural history data as comparator; compelling activity could support conditional marketing authorization.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Selected CRO with LSD and rare pediatric trial experience (milestone toward trial start)</li><li>Received FDA "safe to proceed" letter (October 2025)</li><li>Planned trial initiation in H1 2026 across U.S., Europe and Asia</li><li>PLX-200 is an oral, gemfibrozil-based compound with documented BBB penetration</li><li>Known safety profile of gemfibrozil may accelerate development and reduce costs</li><li>Trial designed as flexible, resource-efficient Phase 2 basket to evaluate multiple LSDs</li><li>Use of natural history controls for CLN2/CLN3 cohorts to provide comparative context</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>SOTERIA is open-label and single-arm (no randomized control arm)</li><li>Efficacy assessment for some cohorts relies on natural history comparators rather than randomized controls</li><li>Outcomes are forward-looking and subject to regulatory, clinical trial and other risks</li><li>Timing and initiation plans subject to change (trial start in H1 2026 is planned, not guaranteed)</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/0b02211f-333b-4417-8289-07131227b765" target="_blank">Original Article</a>
    </div>

    <div class="small">PLYX â€¢ TradersLink AI News</div>
  </div>
</body>
</html>